Flagship Harbor Advisors LLC cut its stake in Sanofi SA (NYSE:SNY) by 40.4% in the third quarter, HoldingsChannel reports. The firm owned 6,819 shares of the company’s stock after selling 4,628 shares during the quarter. Flagship Harbor Advisors LLC’s holdings in Sanofi were worth $307,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. AMG National Trust Bank lifted its position in Sanofi by 2.2% during the second quarter. AMG National Trust Bank now owns 91,760 shares of the company’s stock worth $3,671,000 after purchasing an additional 1,956 shares during the period. Round Table Services LLC bought a new stake in Sanofi during the second quarter worth about $244,000. Huntington National Bank lifted its position in Sanofi by 24.9% during the second quarter. Huntington National Bank now owns 6,037 shares of the company’s stock worth $242,000 after purchasing an additional 1,202 shares during the period. Cornerstone Wealth Management LLC bought a new stake in Sanofi during the second quarter worth about $827,000. Finally, Whittier Trust Co. of Nevada Inc. lifted its position in Sanofi by 396.9% during the second quarter. Whittier Trust Co. of Nevada Inc. now owns 14,550 shares of the company’s stock worth $774,000 after purchasing an additional 11,622 shares during the period. Institutional investors and hedge funds own 7.53% of the company’s stock.
Several research firms recently weighed in on SNY. Argus upped their price objective on shares of Sanofi from $48.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday. ValuEngine raised shares of Sanofi from a “strong sell” rating to a “sell” rating in a research report on Friday, July 20th. Barclays raised shares of Sanofi from an “underweight” rating to an “equal weight” rating in a research report on Thursday, November 1st. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research report on Wednesday, October 31st. Finally, Wolfe Research began coverage on shares of Sanofi in a research report on Tuesday, October 23rd. They set a “market perform” rating for the company. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company’s stock. Sanofi has a consensus rating of “Hold” and a consensus price target of $49.50.
SNY stock opened at $45.59 on Friday. The stock has a market capitalization of $111.91 billion, a PE ratio of 14.57, a P/E/G ratio of 2.53 and a beta of 0.70. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85. Sanofi SA has a 12 month low of $37.43 and a 12 month high of $46.25.
Sanofi (NYSE:SNY) last posted its earnings results on Wednesday, October 31st. The company reported $1.07 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.09. The firm had revenue of $9.39 billion during the quarter, compared to analysts’ expectations of $9.10 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The business’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.71 earnings per share. As a group, analysts anticipate that Sanofi SA will post 3.09 EPS for the current year.
In other news, major shareholder Sanofi sold 104,552 shares of the stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $406.68, for a total value of $42,519,207.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.00% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Flagship Harbor Advisors LLC Has $307,000 Stake in Sanofi SA (SNY)” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.thelincolnianonline.com/2018/11/10/flagship-harbor-advisors-llc-has-307000-stake-in-sanofi-sa-sny.html.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Featured Article: Dow Jones Industrial Average (DJIA)
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.